Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you've stopped semaglutide and want to start again, the key point is this: most people need to go back to the beginning of the dose ladder, not pick up where they left off. How far back depends on how long you've been off it and why you stopped. These are prescription-only medicines, so the decision about where to restart belongs with a prescriber, not a protocol you found online. This guide covers what typically happens, what the clinical evidence says, and what to flag to a clinician before you take your next pen out of the box.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you paused Wegovy because of a stomach bug, a holiday, a supply issue, or just life. A few weeks became a few months, and now you're considering restarting semaglutide. The question most people lead with is whether they can go straight back onto the dose they were taking. The honest answer is: almost certainly not, and attempting it is one of the more common reasons people end up with severe nausea that puts them off the medicine entirely.
Semaglutide has a half-life of roughly one week. After around five weeks off the medicine, it has largely cleared from your system. The GLP-1 receptor sensitivity you built up tolerating higher doses does not sit waiting for you, your gut needs time to readjust again. The NHS medicines page for semaglutide makes clear that dose increases are paced deliberately to reduce gastrointestinal side effects; skipping that pacing on a restart creates the same risks as skipping it the first time around.
There's also the appetite question. Many people find that weight creeps back during a break, sometimes quickly. That is a documented pharmacological effect, not a sign that the treatment failed or that you did something wrong. Our semaglutide overview explains the mechanism in more detail if you want the background before speaking to a prescriber.
The clinical picture for stopping and restarting semaglutide is not one-size-fits-all. Duration of the gap is the single most important variable.
A gap of less than two weeks is generally short enough that continuing at the same dose is reasonable, assuming you are tolerating it well and there are no new health changes. The medicine is unlikely to have fully cleared, and your receptors remain acclimatised. Two weeks is a rough dividing line, not a guarantee; your prescriber may still step you back one level as a precaution.
Gaps of between two weeks and a month occupy a clinical grey zone. Some prescribers will drop back one dose tier; others will hold the current dose and monitor closely for the first two or three weeks. If you are considering restarting Wegovy after a two-week break, a same-day prescriber review is the fastest way to get a personalised answer rather than guessing.
For gaps of four weeks or more, returning to 0.25 mg and re-titrating is the safest default. A month is enough time for your system to reset substantially. If you stopped at 2.4 mg and were away for two months, going back to 0.25 mg is not a setback, it is the clinically appropriate route. Some people move through the lower doses faster the second time, but that still requires prescriber oversight. Pages covering restarting after a longer break and restarting after a month go into the specifics of each scenario.
There is one practical check worth doing right now, before any consultation. Look at the expiry date on any remaining pens and check whether they have been stored correctly in the fridge at 2–8°C throughout. A pen that has been left out or has expired cannot be used, and bringing this information to your prescriber saves time. You should also note the date you took your last injection (approximate is fine) because that single figure shapes every recommendation that follows.
Beyond the pen, think about whether anything significant has changed since you stopped. A new diagnosis, a new medication, a pregnancy, or a major change in weight all shift the clinical picture. The NHS England guidance on weight-management injections is clear that semaglutide is not suitable in pregnancy or while breastfeeding, and a prescriber needs to know about any new medicines because some interactions affect how oral medicines are absorbed.
Once you have those details to hand, a consultation is straightforward. At nume, a GPhC-registered Independent Prescriber reads every consultation personally, on the same day. They will set the right re-entry dose based on your gap, your history, and your current health. You can explore treatment options on our weight-loss treatments page, and if you are also weighing up whether Wegovy remains the right choice after your break, our Wegovy overview gives a full account of the evidence. For cost context if that is part of your thinking, our treatment overview covers what a private prescription includes.
Speak to our prescribers before you restart. Getting the opening dose right is the thing that determines whether you tolerate this medicine well or spend the first fortnight struggling with nausea.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.